AIDS-related Highly Aggressive B-cell Lymphoma
Conditions
Interventions
Case series:immunochemotherapy and molecular targeted therapy
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed and relapsed/refractory AIDS-related highly aggressive B-cell lymphoma; 2. Aged 18-70 years, male or female; 3. Non-pregnant and lactating women; 4. For all women of childbearing age, hCG must be measured by pregnancy test to exclude pregnancy status; 5. For all men of childbearing age, contraception must be used during treatment until 3 months after withdrawal of the drug; 6. Signed Informed consent forms.
Exclusion criteria
Exclusion criteria: 1. Allergies or contraindications to any of the drugs covered by the protocol; 2. Liver and renal function: serum bilirubin >35 umol/L, AST/ALT below two times the upper limit of normal, serum creatinine >150 umol/L; 3. Cardiac disease: including echocardiographic EF 2), electrocardiographic QTc > 470 ms; 4. Pulmonary disease: pulmonary edema, pleural effusion (CTCAE score > 2); 5. Combined with other malignant tumors; 6. Patients with active HAV, HBV, HCV and tuberculosis; 7. Inability to understand or comply with research protocols; 8. Concurrent participation in other clinical investigators; 9. Other conditions that the researchers considered inappropriate for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall surviral rate;Progression-free survival rate; | — |
Countries
China
Contacts
Public ContactRenfang Zhang
Shanghai Public Health Clinical Center
Outcome results
None listed